Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HESTIA3
2017-002421-38Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing ticagrelor with placebo (2 arms). Primary endpoint: Number of vaso-occlusive crises. Started Feb 2018; status: terminated.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2017-002421-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002421-38.